Evidence map›Paper›PMID 34526523›Full record

ArticleScientific reports2021

Use of human PBMC to analyse the impact of obesity on lipid metabolism and metabolic status: a proof-of-concept pilot study.

Andrea Costa, Bàrbara Reynés, Jadwiga Konieczna, Marian Martín, Miquel Fiol, Andreu Palou, Dora Romaguera, Paula Oliver

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Ex VivoBiomolecules · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Andrea CostaNutrigenomics, Biomarkers and Risk Evaluation (NuBE) Group, University of the Balearic Islands (UIB), Palma, Spain.
Bàrbara ReynésNutrigenomics, Biomarkers and Risk Evaluation (NuBE) Group, University of the Balearic Islands (UIB), Palma, Spain.
Jadwiga KoniecznaResearch Group on Nutritional Epidemiology and Cardiovascular Physiopathology (NUTRECOR), University Hospital Son Espases (HUSE), Palma, Spain.
Marian MartínResearch Group on Nutritional Epidemiology and Cardiovascular Physiopathology (NUTRECOR), University Hospital Son Espases (HUSE), Palma, Spain.
Miquel FiolResearch Group on Nutritional Epidemiology and Cardiovascular Physiopathology (NUTRECOR), University Hospital Son Espases (HUSE), Palma, Spain.
Andreu PalouNutrigenomics, Biomarkers and Risk Evaluation (NuBE) Group, University of the Balearic Islands (UIB), Palma, Spain. andreu.palou@uib.es.
Dora RomagueraResearch Group on Nutritional Epidemiology and Cardiovascular Physiopathology (NUTRECOR), University Hospital Son Espases (HUSE), Palma, Spain.
Paula OliverNutrigenomics, Biomarkers and Risk Evaluation (NuBE) Group, University of the Balearic Islands (UIB), Palma, Spain.
Hospital Universitario Son Espases · ESHealth Research Institute of the Balearic Islands · ESUniversitat de les Illes Balears · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral blood mononuclear cells (PBMC) are widely used as a biomarker source in nutrition/obesity studies because they reflect gene expression profiles of internal tissues. In this pilot proof-of-concept study we analysed in humans if, as we previously suggested in rodents, PBMC could be a surrogate tissue to study overweight/obesity impact on lipid metabolism. Pre-selected key lipid metabolism genes based in our previous preclinical studies were analysed in PBMC of normoglycemic normal-weight (NW), and overweight-obese (OW-OB) subjects before and after a 6-month weight-loss plan. PBMC mRNA levels of CPT1A, FASN and SREBP-1c increased in the OW-OB group, according with what described in liver and adipose tissue of humans with obesity. This altered expression pattern was related to increased adiposity and early signs of metabolic impairment. Greater weight loss and/or metabolic improvement as result of the intervention was related to lower CPT1A, FASN and SREBP-1c gene expression in an adjusted linear mixed-effects regression analysis, although no gene expression recovery was observed when considering mean comparisons. Thus, human PBMC reflect lipid metabolism expression profile of energy homeostatic tissues, and early obesity-related alterations in metabolic at-risk subjects. Further studies are needed to understand PBMC usefulness for analysis of metabolic recovery in weigh management programs.

Indexed as

BiomarkersLipid MetabolismAbsorptiometry, PhotonAdolescentAdultBody CompositionBody Weights and MeasuresDisease SusceptibilityFemaleHumansLeukocytes, MononuclearMaleMiddle AgedObesityOverweightPilot ProjectsBiomarkers

Identifiers

PMID34526523
PMCPMC8443582
OpenAlexW3201534241

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.